Dr. Amarpali Brar, MD

Dr. Brar practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Brar's NPI, 1104001718, was assigned on January 2, 2008. Dr. Brar holds California license C154027.

Dr. Brar's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Brar's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Brar to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brar practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Brar's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Brar is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Brar's licenses on file in 2 states: California and New York.

CMS data shows 865 Medicare services from Dr. Brar across 8 procedure codes in 2024, for 283 Medicare patients. Medicare paid $67,652 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 283 Medicare patients who saw Dr. Brar in 2024. The largest group is under 65, with 137 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 61% are also on Medicaid. Their average risk score is 4.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brar's median patient age at 58, with 41% women.

In 2024, Dr. Brar wrote 1,364 Medicare Part D claims for 259 patients. 86% of them were for generic drugs. CMS names the drug for 1,121 of them, across 32 drugs with 11 or more claims each, at $140,118 in total drug cost. In 2023, CMS named 1,448 claims across 35 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Brar for performance year 2024, reported as part of a group. Dr. Brar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brar as offering telehealth.

Dmand AI links 22 papers to Dr. Brar, published from 2011 to 2024. 2017 was the busiest year, with 3. The most frequent topics are Kidney Transplantation, Graft Survival and Kidney Failure, Chronic. Dr. Brar has published most often in Transplant Proc. Dr. Brar's most frequent co-authors are Moro O. Salifu, MD, Rahul M. Jindal, MD and Fasika M. Tedla, MD.

CMS Open Payments shows 8 general payments to Dr. Brar from 6 drug and device companies from 2016 to 2018. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $43.